Studies indicate that B cell receptor activation regulates B cell-derived IL-35 expression through downstream protein kinase D2 (PDK2), suppressing the immune capacity of anti-tumor T cells and fostering PC development. This evidence concerns the gene PRKD2 and neoplasm.